Morning Movers 02/13: (GNOM) (NEP) (REGN) Higher; (CHTP) Lower
Up)
Complete Genomics Inc. (Nasdaq: GNOM) 36% HIGHER; announced today that it has been selected by Mayo Clinic's Center for Individualized Medicine to provide outsourced whole human genome sequencing. Mayo Clinic researchers will now be able to employ Complete Genomics' sequencing service for some of its large-scale whole genome sequencing projects.
Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) 35.5% LOWER; announced that during a presentation at the 14th Annual BIO CEO and Investor Conference president and CEO, Dr. Simon Pedder, plans to provide an update regarding the company's New Drug Application (NDA) forT NORHERA™ (droxidopa), an overview of key issues identified in the FDA briefing document received by the company and anticipated discussion points for the upcoming Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting scheduled for February 23rd. Click here to see the full report.
China North East Petroleum Holding Ltd. (AMEX: NEP) 13.7% HIGHER; shares continuing to breakout after crossing the 200-day SMA at a price around $2.33 on Friday afternoon. Shares closed Friday's session up about 14 percent.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) 10.8% HIGHER; reported Q4 EPS of ($0.37), $0.23 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $123 million versus the consensus estimate of $131.04 million. Sees FY12 Eylea sales in the US of $250-$300 million.
National Bank of Greece (NYSE: NBG) 10.2% HIGHER; traders often use this stock as the way to broadly play the action on Greece. With the approval of the latest austerity package, traders are jumping back in this week.
SeraCare Life Sciences, Inc. (Nasdaq: SRLS) 9.5% HIGHER; has entered into a definitive agreement to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries. Under the terms of the agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share.
Diebold, Inc. (NYSE: DBD) 9.3% HIGHER; reported Q4 EPS of $1.40, $0.56 better than the analyst estimate of $0.84. Revenue for the quarter came in at $850 million versus the consensus estimate of $839.85 million. Sees FY2012 EPS of $2.30-$2.50, versus the consensus of $2.26.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) 35.5% LOWER; announced that during a presentation at the 14th Annual BIO CEO and Investor Conference president and CEO, Dr. Simon Pedder, plans to provide an update regarding the company's New Drug Application (NDA) forT NORHERA™ (droxidopa), an overview of key issues identified in the FDA briefing document received by the company and anticipated discussion points for the upcoming Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting scheduled for February 23rd. Click here to see the full report.
China North East Petroleum Holding Ltd. (AMEX: NEP) 13.7% HIGHER; shares continuing to breakout after crossing the 200-day SMA at a price around $2.33 on Friday afternoon. Shares closed Friday's session up about 14 percent.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) 10.8% HIGHER; reported Q4 EPS of ($0.37), $0.23 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $123 million versus the consensus estimate of $131.04 million. Sees FY12 Eylea sales in the US of $250-$300 million.
National Bank of Greece (NYSE: NBG) 10.2% HIGHER; traders often use this stock as the way to broadly play the action on Greece. With the approval of the latest austerity package, traders are jumping back in this week.
SeraCare Life Sciences, Inc. (Nasdaq: SRLS) 9.5% HIGHER; has entered into a definitive agreement to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries. Under the terms of the agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share.
Diebold, Inc. (NYSE: DBD) 9.3% HIGHER; reported Q4 EPS of $1.40, $0.56 better than the analyst estimate of $0.84. Revenue for the quarter came in at $850 million versus the consensus estimate of $839.85 million. Sees FY2012 EPS of $2.30-$2.50, versus the consensus of $2.26.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Unusual 11 Mid-Day Movers 05/25: (GNOM) (UPI) (RPRX) Higher; (TLB) (DCTH) (PAY) Lower
- Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
- Notable Mergers and Acquisitions of the Day 05/24: (GIS) (GE) (WAIR)
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Morning Movers, SeraCare Life Sciences/Linden Capital PartnersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
